Last updated: February 13, 2026
What is the exact nature of NDC 60505-0829?
NDC 60505-0829 corresponds to Rivaroxaban (brand name Xarelto), a direct oral anticoagulant (DOAC). It is primarily used for preventing and treating blood clots, including atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE).
What is the current market size for Rivaroxaban (Xarelto)?
Market Size (2022-2023):
- Global sales for rivaroxaban totaled approximately $3.7 billion in 2022, with the US accounting for around 55% of the revenue.
- The US market alone generated roughly $2 billion in 2022.
Key Drivers:
- Aging population: increasing prevalence of atrial fibrillation and thromboembolic disorders.
- Cardiovascular disease prevalence: rising cardiovascular risk factors support continued demand.
- Prescribing shift: competes with warfarin, which faces replacement due to ease of use and safety profile of DOACs.
Which companies dominate this market segment?
Market Leaders:
- Johnson & Johnson (through Janssen Pharmaceuticals) markets Xarelto.
- Other competitors include Bayer (co-developer), Pfizer, and Boehringer Ingelheim.
Market share insights:
- Xarelto holds approximately 50% of the DOAC market segment in the US, with dabigatran (Pradaxa) and apixaban (Eliquis) sharing the remaining market.
- The competitive landscape is aggressive, with Bayer and Pfizer’s Eliquis holding about 30% market share globally, but slightly less in the US due to Xarelto’s early entry.
What are the current pricing trends for Xarelto?
Average wholesale price (AWP):
- The AWP for Xarelto tablets ranges between $500 and $700 per month, depending on dosage (10 mg, 15 mg, 20 mg).
- Listed net prices tend to be lower after rebate and discount adjustments, typically 30-40% below AWP in pharmacy benefit plans.
| Price comparisons: |
Dosage |
AWP per month |
Estimated net price |
| 10 mg |
$520 |
$310 – $370 |
| 15 mg |
$620 |
$370 – $440 |
| 20 mg |
$670 |
$400 – $470 |
Pricing pressures:
- Biosimilar entries are limited; no biosimilars for rivaroxaban currently available.
- Price erosion has been relatively stable due to patent protections in major markets, with patent expiry around 2024 in the US.
What innovation or regulatory changes could impact pricing?
Patent Expiry:
- Riveting patent protections expire in the US in 2024, potentially opening the market to biosimilars or generic rivaroxaban.
- Entry of generics could reduce prices by 40-60%, based on historical generic launches.
Regulatory landscape:
- The FDA approved generic rivaroxaban from multiple manufacturers starting mid-2024.
- Over time, increased generic competition is expected to lower prices, making the drug more accessible globally, especially in emerging markets.
Healthcare policies:
- CMS and insurers are increasingly adopting formulary restrictions favoring generics or lower-cost alternatives, pressuring prices lower.
What are the future price projections?
Near-term (2023-2025):
- Expected price stability with minor fluctuations due to rebates, discount arrangements, and rebates.
- Price reductions in the US expected around 10-20%, primarily driven by formulary negotiations.
Medium-term (2026-2030):
- Entry of biosimilars and generics is likely to lower prices between 30% and 50% from current levels, assuming market penetration and regulatory approval.
- Competition will particularly impact the US and European markets, reducing margins for brand-name manufacturers.
Long-term (2030 and beyond):
- Market saturation and technological advances may lead to further price erosion, especially in lower-income regions.
- Innovation in anticoagulant therapy and personalized medicine might stabilize or even increase prices of advanced formulations, but generic versions will likely dominate the lower-end market.
Summary table of projections
| Year |
Price Trend |
Expected Price Impact |
| 2023 |
Stable |
Minor reductions (~10%) due to rebates |
| 2024 |
Moderate reduction |
Patent expiry introduces generics, potential 20-30% price drop |
| 2025 |
Increased competition |
Additional 10-15% reduction |
| 2026-2030 |
Significant price erosion |
30-50% reduction from current retail prices |
Key Takeaways
- The current global market for rivaroxaban surpassed $3.7 billion in 2022, dominated by Xarelto from Johnson & Johnson/Bayer, with the US accounting for over half of sales.
- Pricing for Xarelto remains relatively high, between $520 and $670 per month, but will face significant downward pressure once patent protections expire in 2024, leading to generic entry.
- Price reductions of 30-50% are projected over the next five years due to increased generic competition, impacting revenue streams for brand-name manufacturers.
- Market share shifts, regulatory policies, and biosimilar entry will influence future price dynamics.
FAQs
1. When will generic rivaroxaban become available in the US?
Generic rivaroxaban received FDA approval in mid-2024, with launches expected shortly after regulatory clearance.
2. How much could prices decrease post-generic entry?
Prices are projected to decline by 40-60%, mirroring patterns seen with other oral anticoagulants post-generic approval.
3. What is the primary factor influencing future price trends?
Patent expiration and subsequent generic/biosimilar entry drive price declines.
4. How does the market share distribution look among competing anticoagulants?
Xarelto maintains about 50% of the US DOAC market, with Eliquis taking around 30%, and Pradaxa, Edoxaban, and emerging biosimilars sharing the remainder.
5. How might healthcare policies impact prices?
Formulary restrictions and increased emphasis on cost-effective therapies are likely to lower prices further, especially benefiting generics.
